Brevan Howard Capital Management’s Pacific Biosciences PACB Stock Holding History

Brevan Howard Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.3K	Buy	+10,806	New	+$19.3K	﹤0.01%	2113
2025 Q4	–	Sell	-101,957	Closed	-$131K	–	2160
2025 Q3	$131K	Buy	+101,957	New	+$138K	﹤0.01%	1836
2025 Q2	–	Sell	-14,129	Closed	-$16.7K	–	1964
2025 Q1	$16.7K	Buy	+14,129	New	+$21.7K	﹤0.01%	1118
2024 Q4	–	Sell	-192,956	Closed	-$328K	–	1334
2024 Q3	$328K	Sell	192,956 -29,447	-13%	-$48.4K	﹤0.01%	815
2024 Q2	$305K	Buy	222,403 +182,434	+456%	+$368K	﹤0.01%	769
2024 Q1	$150K	Buy	+39,969	New	+$234K	﹤0.01%	845

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Brevan Howard Capital Management's PACB Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Pacific Biosciences (PACB) in Q1 2026: 10,806 shares worth $14.3K. The stake represents ﹤0.01% of the portfolio and ranks #2113 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in PACB as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in PACB in Q1 2024 and has held it in 6 quarters since. The position peaked at $328K in Q3 2024. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Brevan Howard Capital Management held 10,806 shares of Pacific Biosciences worth $14.3K as of Q1 2026.
Pacific Biosciences was a new Brevan Howard Capital Management position in Q1 2026.
Pacific Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2113 holding.
Brevan Howard Capital Management first reported a position in Pacific Biosciences in Q1 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Pacific Biosciences position peaked at $328K in Q3 2024.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.